Adriana Scheliga

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

Hematological Malignancy, Lymphoid Neoplasia, Mabthera International Trial +7

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +5

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

John P. Leonard, Marek Trněný, Koji Izutsu et al. · Journal of Clinical Oncology · 2019 · 401 citations · Full text

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

Michael Pfreundschuh, Anthony D. Ho, Eva Cavallin‐Ståhl et al. · The Lancet Oncology · 2008 · 221 citations

Hematological Malignancy, Lymphoid Neoplasia, Maximum Tumour +9

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong et al. · The Lancet Oncology · 2011 · 108 citations

Hematological Malignancy, Lymphoid Neoplasia, Rituximab Versus Rituximab +6